Question 1

How do GLP-1 medications work?

Accepted Answer

GLP-1 receptor agonists (such as semaglutide and tirzepatide, the latter of which also activates GIP receptors) mimic incretin hormones produced by the gut. They slow gastric emptying, enhance satiety, modulate central appetite signaling, and improve glycemic regulation. Their pharmacologic effects persist while the medication is taken at a therapeutic dose and diminish over a period of weeks after discontinuation.

Question 2

Which medications are commonly described as GLP-1 therapies?

Accepted Answer

Common examples include semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management) and tirzepatide (Mounjaro for type 2 diabetes and Zepbound for chronic weight management). Liraglutide (Saxenda, Victoza) is an earlier GLP-1 agent. Labeled indications, dosing, and access differ by product and country, and may change over time.

Question 3

Are GLP-1 medications approved for weight management?

Accepted Answer

Several GLP-1 receptor agonists carry regulatory approval for chronic weight management in adults — and in some cases adolescents — who meet specific criteria related to body mass index and weight-related conditions. Others are approved for type 2 diabetes and may be used off-label for weight management at a clinician's discretion. Approved indications are listed in each product's prescribing information.

Question 4

How are GLP-1 medications administered?

Accepted Answer

Most current GLP-1 agonists used for chronic weight management are administered by a once-weekly subcutaneous injection that the patient self-administers. An oral semaglutide formulation also exists and is taken once daily. The right option for a given patient is decided with a prescribing clinician.

Question 5

What is bariatric and metabolic surgery?

Accepted Answer

Bariatric and metabolic surgery refers to a set of procedures that modify gastrointestinal anatomy and downstream neurohormonal signaling to support sustained weight reduction and improvements in metabolic conditions. Common examples include sleeve gastrectomy, Roux-en-Y gastric bypass, one-anastomosis (mini) gastric bypass, and revisional procedures. Endoscopic procedures such as endoscopic sleeve gastroplasty (ESG) are less invasive options that reshape the stomach without external incisions.

Question 6

What is a gastric sleeve procedure?

Accepted Answer

Sleeve gastrectomy is a procedure in which a portion of the stomach is removed, leaving a smaller, tubular ('sleeve-shaped') stomach. It reduces gastric volume and influences hormonal signaling related to hunger and satiety. It is one of the most commonly performed bariatric procedures worldwide.

Question 7

What is a mini gastric bypass?

Accepted Answer

One-anastomosis gastric bypass (often called mini gastric bypass) creates a smaller stomach pouch and a single intestinal connection. It is technically less complex than Roux-en-Y gastric bypass and has its own risk, benefit, and follow-up profile. Eligibility and the choice of procedure are individualized.

Question 8

What is revisional bariatric surgery?

Accepted Answer

Revisional surgery refers to procedures performed after an initial bariatric operation — for example, to address insufficient weight loss, weight regain, reflux, anatomic complications, or other clinical indications. Revisional procedures are technically more complex and require evaluation by a team experienced in this category of care.

Question 9

What is endoscopic sleeve gastroplasty (ESG)?

Accepted Answer

ESG is an endoscopic procedure performed through the mouth, without external incisions, in which sutures are placed inside the stomach to reduce its volume. It is generally considered less invasive than surgical sleeve gastrectomy and has its own evidence base regarding outcomes, durability, and risks.

Question 10

Can GLP-1 medications replace surgery?

Accepted Answer

GLP-1 medications and bariatric or metabolic surgery work through different mechanisms and have different outcome and durability profiles. For some patients, GLP-1 therapy may produce clinically meaningful results without surgery; for others, a procedural option may be considered. Whether either is appropriate is an individualized clinical decision based on BMI, comorbid conditions, prior treatment, surgical history, and patient preferences.

Question 11

Can surgery replace GLP-1 medications?

Accepted Answer

In some patients, after bariatric or metabolic surgery, the need for weight-loss or glucose-lowering medications is reduced — and in certain cases discontinued — based on clinical response. Decisions about discontinuing any prescription medication are made by the prescribing clinician and may evolve over time.

Question 12

Is surgery better than GLP-1 therapy?

Accepted Answer

Current guidance from major specialty societies does not declare one pathway to be universally superior to the other. Each has different mechanisms, follow-up requirements, risk profiles, and durability characteristics. The most appropriate option depends on the individual patient.

Question 13

Which option is right for me?

Accepted Answer

There is no online tool that can answer this question for an individual. A qualified clinician evaluates BMI, comorbid conditions such as type 2 diabetes, NAFLD/MASLD, hypertension, or obstructive sleep apnea, prior treatment history, surgical history, and personal goals and preferences. Shared decision-making is the standard approach.

Question 14

Can both be used together?

Accepted Answer

Yes — pharmacotherapy and surgery are increasingly described as complementary tools within an integrated treatment pathway. GLP-1 medications may be used preoperatively, postoperatively, or to address weight regain after surgery. Whether a combined approach is appropriate is an individualized clinical decision.

Question 15

How do follow-up requirements compare?

Accepted Answer

GLP-1 therapy involves ongoing prescriber visits, dose titration, and continuous medication supply. Surgical pathways involve a structured preoperative evaluation, postoperative recovery, lifelong nutritional follow-up, periodic labs, and behavioral support. Both pathways benefit from longitudinal multidisciplinary care.

Question 16

What happens if I stop a GLP-1 medication?

Accepted Answer

Withdrawal data from large GLP-1 trial programs (for example, a one-year extension of the STEP 1 trial of semaglutide) report substantial weight regain after discontinuation — on average roughly two-thirds of lost weight returned within about one year. Appetite typically returns toward pre-treatment patterns as pharmacologic effects diminish. Discuss any change with the prescribing clinician.

Question 17

Can weight return after bariatric surgery?

Accepted Answer

Yes. While bariatric and metabolic procedures are durable for many patients, a subset experience insufficient initial response or weight regain over time. Causes are multifactorial — anatomic, behavioral, medical, and environmental. Response options may include re-engagement with nutritional and behavioral support, evaluation for anatomic causes, revisional procedures when indicated, or the addition of pharmacotherapy including GLP-1 agents.

Question 18

What happens if weight returns?

Accepted Answer

Weight regain after either pathway is best evaluated by a clinician who can identify contributing factors and discuss options. These may include intensifying behavioral and nutritional support, adjusting or restarting pharmacotherapy, evaluating anatomic causes after surgery, or considering revisional procedures. No single response is uniformly appropriate.

Question 19

What outcomes have been reported with GLP-1 therapy?

Accepted Answer

In published phase-3 trials, average total body-weight reductions reported with current GLP-1 receptor agonists at therapeutic doses (with concurrent lifestyle support) have ranged in the mid-teens to low-twenties percent over 68–72 weeks. Individual response varies. Glycemic, blood-pressure, and lipid effects have also been reported. Refer to each product's labeled information for trial-specific details.

Question 20

What outcomes have been reported with bariatric surgery?

Accepted Answer

Long-term cohorts and trials such as STAMPEDE, SLEEVEPASS, and SM-BOSS report meaningful and durable weight reductions and improvements in conditions such as type 2 diabetes, hypertension, and sleep apnea for many patients undergoing sleeve gastrectomy or gastric bypass. Outcomes vary by patient, procedure, and adherence to follow-up. Surgery is not a guarantee of any specific outcome.

Question 21

What are the most common side effects of GLP-1 medications?

Accepted Answer

Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are the most commonly reported, especially during dose escalation, and often improve over time. Other considerations include gallbladder events, rare pancreatitis, changes in lean body mass, and contraindications related to personal or family history of medullary thyroid carcinoma or MEN-2. Each product's labeled prescribing information should be reviewed.

Question 22

What are the risks of bariatric surgery?

Accepted Answer

As with any major surgical procedure, risks include bleeding, infection, anastomotic or staple-line complications, venous thromboembolism, nutritional deficiencies, dumping syndrome (with bypass procedures), and procedure-specific complications. Performed in accredited centers, 30-day mortality for primary bariatric surgery is reported to be in the low single digits per 1,000 in contemporary registry data. Long-term follow-up is essential.

Question 23

Are there contraindications to GLP-1 medications?

Accepted Answer

Yes. Contraindications and warnings listed on product labels include personal or family history of medullary thyroid carcinoma, MEN-2, and known serious hypersensitivity to the medication or its components. Caution is also discussed in settings such as severe gastrointestinal disease, pancreatitis history, and pregnancy. The prescribing clinician reviews these considerations.

Question 24

Are there contraindications to surgery?

Accepted Answer

Bariatric and metabolic surgery may not be appropriate in patients with certain uncontrolled medical conditions, active substance use that has not been addressed, or other situations identified during the multidisciplinary evaluation. Eligibility is determined by the surgical and medical team after a full evaluation.

Question 25

What nutritional considerations follow surgery?

Accepted Answer

After bariatric procedures, patients typically follow a staged diet during recovery and adopt ongoing protein, hydration, vitamin, and mineral practices. Periodic micronutrient laboratory monitoring is part of standard follow-up. Adherence to nutritional guidance is associated with better long-term outcomes.

Question 26

How much do GLP-1 medications cost?

Accepted Answer

U.S. list prices for branded GLP-1 agents have been widely reported in the range of several hundred to over one thousand U.S. dollars per monthly supply, before insurance adjustments and manufacturer programs. Out-of-pocket cost depends on the specific product, dose, insurance benefit design, and any patient-assistance program.

Question 27

How much does bariatric surgery cost?

Accepted Answer

Surgical pricing varies substantially by country, hospital, payer arrangement, and procedure. A typical episode of care includes the procedure, anesthesia, facility fees, perioperative testing, hospital stay, and immediate follow-up. Self-pay and international packages exist; patients are encouraged to request itemized written estimates and a clear description of what is and is not included.

Question 28

Does insurance cover these options?

Accepted Answer

Coverage policies for both pharmacologic and surgical pathways vary by plan and by year. Coverage of GLP-1 medications for weight management in particular has been variable, and patients should confirm current benefit details with their insurer in writing.

Question 29

How should I plan for long-term cost?

Accepted Answer

Because obesity is recognized as a chronic, relapsing condition, cost planning is most accurate over a multi-year horizon. Patients can ask their clinician and insurer about typical out-of-pocket scenarios over 1, 3, and 5 years, including medication, follow-up, labs, and possible complication management.

Question 30

Which patients may benefit from a metabolic evaluation?

Accepted Answer

A clinical evaluation is generally appropriate when obesity or related conditions are affecting health, when previous treatment attempts have not produced sustained results, or when a patient is considering starting, changing, or stopping a weight-related therapy. Eligibility for any specific pathway is determined by a qualified clinician.

Question 31

What BMI thresholds are commonly discussed?

Accepted Answer

Updated guidance from ASMBS and IFSO (2022) describes lower BMI thresholds for considering metabolic and bariatric surgery than older criteria, particularly in the presence of clinically significant obesity-related conditions. GLP-1 therapy is discussed across a range of BMI categories, with eligibility shaped by labeled indications and clinical context.

Question 32

How long does an evaluation take?

Accepted Answer

A complete bariatric or metabolic evaluation typically involves multiple visits over weeks to months and includes medical, nutritional, behavioral, and — when indicated — sleep, cardiology, gastroenterology, or endocrinology input. The timeline depends on the program and the patient's complexity.

Question 33

Can I be evaluated if I have had prior surgery?

Accepted Answer

Yes. Patients with prior abdominal or bariatric surgery can be evaluated for further options, including revisional procedures or non-surgical pathways. Evaluation by a team experienced in revisional care is recommended.

Question 34

Do I still need to focus on nutrition and exercise?

Accepted Answer

Yes. Neither pharmacotherapy nor surgery eliminates the need for sustained nutritional and physical-activity patterns. Society guidance consistently describes lifestyle support as a foundation for any treatment pathway.

Question 35

How important is behavioral support?

Accepted Answer

Behavioral support — addressing eating patterns, stress, sleep, and other modifiable factors — is associated with better long-term outcomes across both pharmacologic and surgical pathways. Many accredited programs integrate behavioral health into routine care.

Question 36

How long should follow-up continue?

Accepted Answer

Obesity is recognized by major specialty societies as a chronic, relapsing condition. Follow-up — clinical visits, labs, behavioral and nutritional support — is generally framed as long-term rather than time-limited, regardless of which pathway is chosen.

Question 37

What if I travel internationally for surgery?

Accepted Answer

International patients should expect coordination with their home-country clinicians for ongoing follow-up. Well-organized programs provide written summaries of the procedure, perioperative care, and recommended follow-up that can be shared with a primary care physician.

Frequently Asked Questions

Medical Review & Clinical Oversight

Medical Reviewers

Dr. Ariel Ortiz Lagardere, MD, FACS, FASMBS

Dr. Arturo Martinez Gamboa, MD

Dr. Helmuth Billy, MD

Editorial Review Process

Educational Disclaimer

References

GLP-1 medications: basics

Bariatric and metabolic surgery: basics

Comparing pathways

Outcomes, durability, and regain

Risks and safety

Costs and access

Eligibility and evaluation

Long-term lifestyle and follow-up